EnteroMedics Inc. (NASDAQ: ETRM) 72.6% LOWER; announced preliminary results from its EMPOWER Study. Based on an initial analysis, the study did not meet its primary and secondary efficacy endpoints. There were no therapy-related serious adverse events reported in the study. The EMPOWER Study is a randomized, double-blind, placebo-controlled pivotal study designed to evaluate the safety and effectiveness of the Maestro(R) System for the treatment of obesity.

CIT Group Inc. (NYSE: CIT) 20.8% HIGHER; commenced a restructuring of its capital structure that has been approved by the Company’s Board of Directors and by the Steering Committee of CIT’s bondholders. Under